Case Report

Breast Implant-Associated Anaplastic Large Cell Lymphoma: Case Report and Review of the Literature

Eva Berlin, Kunwar Singh, Christopher Mills, Ilan Shapira, Richard L. Bakst, and Manjeet Chadha

1Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
2Department of Pathology, Mount Sinai Downtown, New York, NY 10003, USA
3Department of Surgery, Mount Sinai Downtown, New York, NY 10003, USA
4Department of Medicine, Mount Sinai Downtown, New York, NY 10003, USA
5Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY 10029, USA
6Department of Radiation Oncology, Mount Sinai Downtown, New York, NY 10003, USA

Correspondence should be addressed to Manjeet Chadha; manjeet.chadha@mountsinai.org

Received 31 August 2017; Accepted 4 December 2017; Published 21 January 2018

1. Introduction

Anaplastic large cell lymphoma (ALCL), a peripheral T cell lymphoma, represents approximately 2 to 3% of all non-Hodgkin’s lymphomas [1]. Subtypes of ALCL can be grouped by the presence or absence of anaplastic lymphoma kinase (ALK) surface receptor and also by primary site of involvement, that is, primary cutaneous ALCL and breast implant-associated (BIA) ALCL [2]. BIA-ALCL is ALK negative, and similar to ALK positive and ALK negative ALCL, it is characterized by eccentric, horseshoe-shaped nuclei called “hallmark cells.” Unlike other types of ALCL, BIA-ALCL rarely invades beyond the breast. BIA-ALCL is distinct from primary breast lymphoma, which is composed of B cells and originates from the breast parenchyma.

The estimated incidence of BIA-ALCL is 2.03 per 1 million person years with an estimated prevalence of 1 per 30,000 women with breast implants [3]. The first case report of BIA-ALCL was published in 1997 by Keech and Creech [4]. In 2016, almost two decades later the World Health Organization labeled BIA-ALCL as a distinct entity [5]. Given widespread use of breast implants, there is an increased awareness of the risk for developing BIA-ALCL albeit rare.

In this paper, we describe a patient who was diagnosed with invasive BIA-ALCL two years after placement of silicone breast implants and was treated with multimodality therapy, that is, surgery, adjuvant chemotherapy, and locoregional radiation.

2. Case Report

A 58-year-old female underwent bilateral breast lift and augmentation with silicone implants in September 2012. In August 2014, she presented with right breast swelling and heaviness in the inferior aspect of the breast. The
patient denied weight loss, night sweats, fevers, chills, or systemic complaints. Imaging including mammogram and bilateral breast ultrasound noted presence of fluid surrounding the entire visible right breast implant. Presence of a 2 cm mass in the lower inner quadrant of the right breast and an enlarged 3 cm right axillary lymph node was also confirmed on MRI (Figure 1). Staging PET/CT showed multiple lesions in the right breast, the largest measuring up to 5 cm with SUV ranging from 10 to 52.4 (Figure 2(a)) and two hypermetabolic lymph nodes in the right axilla measuring 1.7 and 3.7 cm with SUV of 6.0 and 15.8, respectively (Figure 2(c)). There was also a hypermetabolic band posterior to the implant involving the pectoralis minor muscle measuring 5 × 1 cm with an SUV of 33.7 (Figure 2(e)). Bone marrow biopsy was not performed. The biopsies of the breast, right axillary lymph nodes, and fluid cytology surrounding the breast capsule confirmed CD30+/ALK− anaplastic large cell lymphoma (Figure 3).

Multidisciplinary treatment plan included bilateral capsulectomy and right partial mastectomy with excision of the right breast mass and no axillary surgery. The right axillary node was intentionally left in place to serve as a correlate to the response to systemic chemotherapy during the postoperative period. At the time of surgery, all gross disease was removed; however, there was disease adherent to the chest wall in the area posterior to the dominant lesion of lower inner quadrant of the right breast. It was assumed that there would be residual microscopic disease in this area and that postoperative RT to the chest wall would be indicated, regardless of the results of a postoperative PET/CT scan. Surgical pathology noted residual lymphoma in the fibroconnective tissue of the right breast chest wall. In addition, surgical pathology confirmed areas of disease found on the pretreatment imaging (Figures 1, 2(a), 2(c), and 2(e)), including the right breast capsule, right breast extracapsular tissue, right medial breast glandular tissue, and right breast chest wall. Postoperatively, the patient received 6 cycles of adjuvant CHOP chemotherapy, which she tolerated well. PET/CT after 3 cycles of chemotherapy showed complete resolution of the previously noted hypermetabolic areas in the right breast (Figure 2(b)) and chest wall (Figure 2(f)), as well as a decrease in size of the right axillary lymph nodes to 0.5 cm (from 1.7 to 3.7 cm) (Figure 2(d)). Subsequent to completing chemotherapy, the patient received radiation to the right breast and regional nodes. A total dose of 3600 cGy in 20 fractions using 180 cGy per fraction was delivered over 4 weeks. The patient tolerated the therapy well.

Since completing treatments, the patient has been followed by the multidisciplinary team at regular intervals and has not required subsequent therapy. At present follow-up 2.5 years from diagnosis, the patient remains without evidence of disease on physical exam and PET/CT scans.

3. Discussion

Advances in plastic surgery introduced the first breast augmentation procedure in 1962 [6]. Since then, there has been a steady rise in the number of patients undergoing breast augmentations. Worldwide, approximately 1.4 million breast augmentations were performed in 2015 [7]. In the United States, 290,467 breast augmentations were performed in 2016; this represented a 37% increase from 2000 [8].

BIA-ALCL most commonly occurs in patients of a median age of 52 years. The median time interval between breast implant and diagnosis is 9 years and ranges from 1 to 32 years [9]. Common presenting symptoms include swelling, pain, and redness of the affected breast [10]. Lymphadenopathy is a less common presenting symptom, found in one in 8 patients [11]. In most patients, BIA-ALCL occurs as a periprosthetic malignant effusion (∼70%), whereas the minority present with a capsular mass in addition to an effusion (∼30%) [9]. For staging and prognostication, the MD Anderson tumor, lymph node, metastasis (TNM) system of BIA-ALCL was proposed by Clemens et al. and is based on the American Joint Committee on Cancer TNM staging for solid tumors [12].

The pathogenesis of BIA-ALCL is unknown, but its association with textured implants is well recognized [3, 13]. By 2017, the FDA accumulated 359 medical device reports of BIA-ALCL with the majority of cases reported in textured implants versus smooth implants: 203 of the 231 medical
device reports that included implant surface texture type were textured implants, and 28 were reported to be smooth implants [13]. Recent studies have theorized that chronic inflammation caused by bacterial biofilm of textured implants may mediate T cell hyperplasia and development of ALCL [14–16]. Hu et al. studied the biofilm response to implants in both pigs and humans and found that there was increased lymphocytic response in textured implants compared to smooth implants ($P < 0.001$) [15]. Loch-Wilkinson et al. also observed an association between increased surface area in textured implants and risk for developing BIA-ALCL. This suggests that environmental factors may trigger bacterial proliferation and T cell activation with chronic inflammation, resulting in increased risk of ALCL [16]. Kadin et al. proposed that BIA-ALCL is linked to chronic bacterial antigen stimulation of Th1/Th17 antigen-driven memory T cells in their study of biomarkers in the pathogenesis of BIA-ALCL [17].

![Figure 2](image-url)
In general, the prognosis of BIA-ALCL is excellent (Table 1). The patients have median survivals in the range 12 to 13 years. The FDA recorded 2.5% deaths from the 359 medical device reports [13]. Despite the overall excellent prognosis, there are certain presentations that are associated with worse prognosis. In a 2014 study by Miranda et al. of long-term follow-up of 60 patients with BIA-ALCL, those who had a mass were shown to have worse survival rates at 3 and 5 years. Patients have median survivals in the range 12 to 13 years. The FDA recorded 2.5% deaths from the 359 medical device reports [13]. Despite the overall excellent prognosis, there are certain presentations that are associated with worse prognosis. In a 2014 study by Miranda et al. of long-term follow-up of 60 patients with BIA-ALCL, those who had a mass were shown to have worse survival rates at 3 and 5 years.
years compared to those without a mass [9]. A meta-analysis of 62 patients by Hart and Lechowicz noted that patients with a mass had an increased risk of death (P = 0.043) and patients with extracapsular disease extension had an increased risk of recurrence (P < 0.001) and death (P = 0.0008) [18]. In a 2016 study by Clemens et al., patients with lymphoma that spread beyond the capsule had a worse event-free survival [12].

Review of literature notes that among operable patients, total capsulectomy with removal of suspicious lymph nodes is the first line of treatment [12, 19, 20]. Among the 87 patients described in a study by Clemens et al., complete surgical excision (capsulectomy and implant removal) resulted in better overall survival and event-free survival compared to patients who underwent a limited surgery or treatment with systemic chemotherapy or radiation therapy [12]. A multidisciplinary approach is used in cases of BIA-ALCL that are not completely removed by surgery and patients presenting with high risk and advanced disease [20]. Table 2 is a summary of multidisciplinary treatment in patients presenting with mass and/or lymph node involvement and effusion. Postoperative radiation is given in high-risk patients including those with extensive disease, subtotal resection, positive margins, and chest wall invasion. In the case of locally advanced disease, lymph node involvement, or distant organ metastasis, systemic chemotherapy is given using either a combination of anthracycline-based chemotherapy (CHOP) or brentuximab vedotin (anti-CD30 antibody).

The management of patients with this rare disease has to be individualized. Our patient presented with high-risk features including effusion, chest wall mass, and lymphadenopathy received multimodality therapy and achieved an excellent response.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

[1] The Non-Hodgkin’s Lymphoma Classification Project, “A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma,” Blood, vol. 89, no. 11, pp. 3909–3918, 1997.
[2] D. Chihara and M. A. Fanale, “Management of anaplastic large cell lymphoma,” Hematology/Oncology Clinics of North America, vol. 31, no. 2, pp. 209–222, 2017.
[3] E. L. Doren, R. N. Miranda, J. C. Selber et al., “U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma,” Plastic and Reconstructive Surgery, vol. 139, no. 5, pp. 1042–1050, 2017.
[4] J. A. Keech Jr and B. J. Creech, “Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant,” Plastic and Reconstructive Surgery, vol. 100, no. 2, pp. 554–555, 1997.
[5] S. H. Swerdlow, E. Campo, S. A. Pileri et al., “The 2016 revision of the World Health Organization classification of lymphoid neoplasms,” Blood, vol. 127, no. 20, pp. 2375–2390, 2016.
[6] T. D. Cronin and F. J. Gerow, “Augmentation mammoplasty; a new “natural feel” prosthesis,” Transactions of the Third International Congress of Plastic Surgery, Excerpta Medica, vol. 66, pp. 41–49, Excerpta Medica, Amsterdam, Netherlands, 1963.
[7] ISOP Surgery, ISAPS International Survey on Aesthetic/Cosmetic Procedures Performed in 2015, June 2017, http://www.isaps.org/Media/Default/global-statistics/2016%20ISAPS%20Results.pdf.
[8] ASOP Surgeons, 2016 National Plastic Surgery Statistics, June 2017, https://d2wirczt3b6wm.cloudfront.net/News/Statistics/2016/2016-plastic-surgery-statistics-report.pdf.
[9] R. N. Miranda, T. N. Aladilly, H. M. Prince et al., “Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients,” Journal of Clinical Oncology, vol. 32, no. 2, pp. 114–20, 2014.
[10] C. A. Gidengil, Z. Predmore, S. Mattke, K. van Busum, and B. Kim, “Breast implant-associated anaplastic large cell lymphoma: a systematic review,” Plastic and Reconstructive Surgery, vol. 135, no. 3, pp. 713–720, 2015.
[11] M. W. Clemens and R. N. Miranda, “Coming of age: breast implant-associated anaplastic large cell lymphoma after 18 years of investigation,” Clinics in Plastic Surgery, vol. 42, no. 4, pp. 605–613, 2015.
[12] M. W. Clemens, L. J. Medeiros, C. E. Butler et al., “Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma,” Journal of Clinical Oncology, vol. 34, no. 2, pp. 160–168, 2016.
[13] UFAD Administration, Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), June 2017, https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/Implantsand Prosthetics/BreastImplants/ucm239995.htm.
[14] H. Hu, K. Johani, A. Almatroudi et al., “Bacterial biofilm infection detected in breast implant-associated anaplastic large-cell lymphoma,” Plastic and Reconstructive Surgery, vol. 137, no. 6, pp. 1659–1669, 2016.
[15] H. Hu, A. Jacombs, K. Vickery, S. L. Merten, D. G. Pennington, and A. K. Deva, “Chronic biofilm infection in breast implants is associated with an increased T-cell lymphocytic infiltrate: implications for breast implant-associated lymphoma,” Plastic and Reconstructive Surgery, vol. 135, no. 2, pp. 319–329, 2015.
[16] A. Loch-Wilkinson, K. J. Beath, R. J. W. Knight et al., “Breast implant associated anaplastic large cell lymphoma in Australia and New Zealand—high surface area textured implants are associated with increased risk,” Plastic and Reconstructive Surgery, vol. 140, no. 4, pp. 645–654, 2017.
[17] M. E. Kadin, A. Deva, H. Xu et al., “Biomarkers provide clues to early events in the pathogenesis of breast implant-associated anaplastic large cell lymphoma,” Aesthetic Surgery Journal, vol. 36, no. 7, pp. 773–781, 2016.
[18] A. Hart and M. J. Lechowicz, “Breast implant-associated anaplastic large cell lymphoma: treatment experience in 53 patients,” Blood, vol. 122, no. 21, p. 5089, 2013.
[19] The Plastic Surgery Foundation, Frequently Asked Questions (FAQ): A Guide to Breast Implant-Associated Anaplastic Large Cell Lymphoma, 2017, https://www.thepsf.org/Documents/Clinical/PROFILE/profile-faq.pdf.
[20] M. W. Clemens and S. M. Horwitz, “NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma,” Aesthetic Surgery Journal, vol. 37, no. 3, pp. 285–289, 2017.
[21] A. Zimmerman, F. L. Locke, J. Emole et al., “Recurrent systemic anaplastic lymphoma kinase-negative anaplastic large cell lymphoma presenting as a breast implant-associated lesion,” Cancer Control, vol. 22, no. 3, pp. 369–373, 2015.
[22] M. J. Hwang, H. Brown, R. Murrin, N. Momtahan, and G. D. Sterne, “Breast implant-associated anaplastic large cell lymphoma: a case report and literature review,” *Aesthetic Plastic Surgery*, vol. 39, no. 3, pp. 391–395, 2015.

[23] M. Parthasarathy, J. Orrell, C. Mortimer, and L. Ball, “Chemotherapy-resistant breast implant-associated anaplastic large cell lymphoma,” *BMJ Case Reports*, vol. 2013, 2013.

[24] J. C. Tardio and R. Granados, “Axillary lymphadenopathy: an outstanding presentation for breast implant-associated ALK-negative anaplastic large cell lymphoma,” *International Journal of Surgical Pathology*, vol. 23, no. 5, pp. 424–428, 2015.

[25] M. A. Bautista-Quach, A. Nademanee, D. D. Weisenburger, W. Chen, and Y. S. Kim, “Implant-associated primary anaplastic large-cell lymphoma with simultaneous involvement of bilateral breast capsules,” *Clinical Breast Cancer*, vol. 13, no. 6, pp. 492–495, 2013.

[26] E. V. George, J. Pharm, C. Houston et al., “Breast implant-associated ALK-negative anaplastic large cell lymphoma: a case report and discussion of possible pathogenesis,” *International Journal of Clinical and Experimental Pathology*, vol. 6, no. 8, pp. 1631–1642, 2013.

[27] I. M. De Silva, J. A. Teague, and W. E. Blake, “Breast implant associated anaplastic large cell lymphoma: a case report and reconstructive option,” *Journal of Plastic, Reconstructive, and Aesthetic Surgery*, vol. 66, no. 12, pp. 1773–1776, 2013.

[28] T. J. Smith and R Ramsaroop, “Breast implant related anaplastic large cell lymphoma presenting as late onset peri-implant effusion,” *Breast*, vol. 21, no. 1, pp. 102–104, 2012.

[29] A. K. Wong, J. Lopategui, S. Clancy, D. Kulber, and S. Bose, “Anaplastic large cell lymphoma associated with a breast implant capsule: a case report and review of the literature,” *American Journal of Surgical Pathology*, vol. 32, no. 8, pp. 1265–1268, 2008.

[30] K. Sorensen, J. Murphy, A. Lennard, V. Wadehra, G. K. Menon, and N. Collis, “Anaplastic large cell lymphoma in a reconstructed breast using a silicone implant: a UK case report,” *Journal of Plastic, Reconstructive, and Aesthetic Surgery*, vol. 67, no. 4, pp. 561–563, 2014.